Study of Pregabalin (an Approved Drug) For the Treatment of Pain Associated with PHN, Conducted at Several Clinical Sites Where all Patients Enrolled Receive Pregabalin.

Registry ID
EUCTR2011-005972-41
Source registry
EUCTR
Status
Prematurely Ended
Phase
PHASE4
Sponsor
Pfizer Inc. 235 East 42nd Street, New York, NY 10017
Start date
2012-08-22
Completion date
2013-06-12
Last update
2026-08-16

Conditions

Summary

The primary objective is to obtain pilot prospective data to explore whether sensory symptom cluster analysis is useful for predicting treatment response in PHN. - Phenotype PHN subjects entering study with sensory symptom clustering using the PainPREDICT, PainDETECT and NPSI questionnaires, “baseline pain interference with sleep”, Patient Health Questionnaire 8 (PHQ-8), Generalized Anxiety Disorder 7-item (GAD-7), as well as Pain Catastrophizing Scale (PCS) questionnaire. - Find “responders” and “non-responders” to treatment (pregabalin). - Compare distribution of phenotypes within “responder” and “non-responder” groups.

Locations

View on source registry